Vaishali Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
VAISHALI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Vaishali Pharma Limited reported standalone revenue from operations of Rs. 10,877.23 Lakhs for FY26, up 9.8% from Rs. 9,902.56 Lakhs in FY25. Net profit surged to Rs. 403.17 Lakhs from Rs. 81.74 Lakhs in the prior year, representing growth of approximately 393%. The auditors issued an unmodified opinion but included an emphasis of matter noting substantial receivables over 3 years old (trade receivables Rs. 5,077.26 Lakh, deposits/loans Rs. 3,199.85 Lakh, other current assets Rs. 2,344.86 Lakh) where they could not comment on potential adjustments needed. Trade receivables of Rs. 226.90 Lakh were written off during the year. The company also acquired a 20.32% stake in Kesar Pharma Limited in September 2025, which is now consolidated as an associate. Operating cash flow was negative at Rs. 30.57 Lakhs for FY26.
Strong profit growth and revenue expansion are positives, but the auditor's emphasis on old receivables and negative operating cash flow raise concerns about working capital management and asset quality. Shareholders should monitor collection efficiency and debt levels.